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Background: Myeloproliferative neoplasms are Philadelphia chromosome-negative diseases
characterized by hyperproliferation of mature myeloid cells, associated or not with the Janus
kinase 2 tyrosine kinase mutation, JAK2V617F. As there is no curative therapy, researchers
have been investigating new drugs to treat myeloproliferative neoplasms, including l-amino
acid oxidase from Calloselasma rhodostoma snake venom (CR-LAAO), which is a toxin capable
of  eliciting apoptosis in several tumor cell lines.
Objective: To evaluate the effects of l-amino acid oxidase from C. rhodostoma snake venom
in  the apoptotic machinery of JAK2-mutated cell lines.
Methods: The HEL 92.1.7 and SET-2 cell lines were cultured with l-amino acid oxidase and
catalase for 12 h at 37 ◦C in 5% carbon dioxide. The cell viability was assessed by the multi-
table tournament method, the level of apoptosis was measured by ﬂow cytometry, and the
expression of cysteine-dependent aspartate-speciﬁc proteases and cleaved Poly(ADP-ribose)
polymerase were analyzed by Western blotting.
Results: l-Amino acid oxidase from C. rhodostoma snake venom was cytotoxic to HEL 92.1.7
and SET-2 cells (50% inhibitory concentration = 0.15 g/mL and 1.5 g/mL, respectively) and
induced apoptosis in a concentration-dependent manner. Cell treatment with catalase
mitigated the l-amino acid oxidase toxicity, indicating that hydrogen peroxide is a key com-
ponent of its cytotoxic effect.The activated caspases 3 and 8 expression and cleaved PARP
in  HEL 92.1.7 and SET-2 cells conﬁrmed the apoptosis activation by CR-LAAO.
Conclusions: l-Amino acid oxidase from C. rhodostoma snake venom is a potential anti-
neoplastic agent against HEL 92.1.7 and SET-2 JAK2V617F-positive cells as it activates the
extrinsic apoptosis pathway.© 2016 Associac¸a˜o Bra
by  Elsevier Editora Lt
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yeloproliferative neoplasms (MPN) are hematological neo-
lasms with similar phenotypic features, preserved cell
aturation, and hyperproliferation of one or more  blood cell
ypes. MPN  comprise chronic myeloid leukemia (CML), poly-
ythemia vera (PV), essential thrombocythemia (ET), primary
yeloﬁbrosis (PMF), chronic neutrophilic leukemia, chronic
osinophilic leukemia, mastocytosis, and non-classiﬁable
PN.1 Patients with PV, ET, and PMF  are negative for the
reakpoint Cluster Region-Abelson Leukemia (Bcr-Abl) oncogene,
nd their hematopoietic progenitors are independent and
ypersensitive to numerous cytokines.2,3 Mutation in the
anus kinase 2 (JAK2) tyrosine kinase is the predominant
olecular alteration in MPN; it is characterized by a guanine-
o-thymine transversion at nucleotide 1849 of exon 14 of the
ene (chromosome 9), resulting in the substitution of valine
or phenylalanine at position 617 (JAK2V617F).4
The amino acid exchange occurs in the JH2 pseudokinase
omain and leads to the loss of the autoinhibitory control of
he JH2 domain over the JH1 domain, and the consequent con-
titutive activation of the protein.5 Jekarl et al.6 reported that
he JAK2V617F mutation is found in 95% of PV patients and in
0% of patients with ET and MF.  In addition to the JAK2V617F
utation, other gene mutations such as JAK2 exon 12, MPL
nd calreticulin may help in the differential diagnosis, patho-
enesis, and prognosis of Philadelphia chromosome-negative
Ph−) MPN.7 It is well known that the pathogenesis of MPN  is
lso linked to genetic and epigenetic alterations and myeloid
ell resistance to apoptosis.5,8,9
Apoptosis is the physiological process of programmed cell
eath that plays a role in the maintenance of cell number
nd integrity, and tissue development in a variety of body sys-
ems. Activation of apoptosis occurs mainly via the intrinsic
nd extrinsic pathways,10 both of which require the par-
icipation of cysteine-dependent aspartate-speciﬁc proteases
caspases). Caspases are proteases bearing a catalytic cys-
eine residue that cleaves other proteins at their aspartic
cid residue. Caspases are synthesized as inactive precursors
zymogens) that require cleavage by proteases to form active
nzymes, which in turn trigger a reaction cascade that culmi-
ates in cell apoptosis.10
Many  types of stimuli can elicit the intrinsic or mito-
hondrial apoptosis pathway, including hypoxia, intracellular
tress, lack of growth factors, irradiation, chemotherapeutic
gents, bacteria, and viruses. These stimuli induce the release
f cytochrome c, apoptosis inducing factor (AIF), second
itochondria derived activator of caspases/direct inhibitor of
poptosis-binding protein with low pI (SMAC/DIABLO), which
ulminates in the activation of apoptotic protease activating
actor-1 (APAF-1). The binding of APAF-1 to deoxyadenosine
riphosphate (ATP)/2 deoxy-ATP (dATP) induces the forma-
ion of the apoptosome, a multimeric complex that activates
he initiator caspase-9 and subsequently activates the execu-
ioner caspases -3, -6, and -7.11The extrinsic apoptosis pathway is triggered by the binding
f ligands to death receptors. These include FAS (FAS/CD95),
umor necrosis factor (TNF) death receptors 1 and 2 (TNF-R1
nd R2, respectively), TNF-related apoptosis-inducing ligand 1 6;3  8(2):128–134 129
receptors (TRAIL) R1 and R2 (DR4 and DR5, respectively); a
family of transmembrane proteins bearing a cysteine-rich
extracellular domain and an intracellular domain named
“death domain” (DD), which is responsible for transducing the
apoptotic signal. The receptor-ligand binding recruits adap-
tor molecules such as FADD (FAS associated with DD)  and
TRADD (TNFR1 associated with DD); it also elicits intracellular
signaling pathways that activate the initiator caspases -8, -9,
and -10 and the executioner caspases -3, -6, and -7, and pro-
motes the formation of apoptotic bodies (cell death). Finally,
macrophages phagocytose the apoptotic bodies.12
Despite extensive knowledge on the pathogenesis of MPN,
scientists have neither stratiﬁed the disease nor discovered
effective treatments to cure it yet. The current treatments
for PV, ET, and PMF rely on palliative therapies (bleeding,
hydroxycarbamide, interferon-, busulfan, corticoids, and
androgens), supportive therapies (blood transfusion, growth
factors, erythropoietin, and antibiotics), allogeneic bone mar-
row transplant, and JAK2 inhibitors.13 Bone marrow transplant
is the only treatment that can change the course of the dis-
ease; however, the success of this therapy is restricted to a
small group of young patients who receive bone marrow from
a human leukocyte antigen (HLA)-compatible donor. JAK2
inhibitors have exerted promising effects in patients with PMF,
including those who are negative for the JAK2V617F muta-
tion. Recent studies have evidenced the beneﬁcial effects of
JAK2 inhibitors on the treatment of patients with PMF, such
as decreased spleen volume, body weight gain, delayed bone
marrow ﬁbrosis, and improved overall survival.14
In this sense, researchers have sought for new drugs
and therapies to treat and cure patients with MPN. Snake
venoms are one of the antitumor agents under investi-
gation; these proteins exert a variety of pharmacological
activities that inﬂuence the clinical manifestations of the
disease, such as apoptosis induction.15 Snake venoms have
complex compositions with different contents of proteins,
peptides, carbohydrates, lipids, biogenic amines, nucleotides,
and amino acids. The major component of the venom of the
Calloselasma rhodostoma, a snake from Vietnam, Cambodia,
Thailand and Malaysia is l-amino acid oxidase (LAAO), which
is a ﬂavoenzyme that catalyzes the oxidative deamination of l-
amino acids to -ketoacid and produces ammonia and H2O2 as
byproducts.16 The secondary effects of H2O2 seem to account
for most of the biological effects of C. rhodostoma LAAO (CR-
LAAO), including apoptosis induction.17
To improve the understanding on the biological activity and
pharmacological potential of LAAOs, the present study aims to
examine the effects of CR-LAAO on the apoptosis machinery
of JAK2V617F-positive cell lines obtained from MPN  patients.
Method
Cell  lines  and  culture
JAK2V617F-positive cell lines HEL 92.1.7 and SET-2 were
obtained from patients with erythroleukemia and post-ET
megakaryoblastic leukemia, respectively. The cell lines were
kindly provided by Dr. Thomas Radimerski (Novartis, Switzer-
land). The HEL 92.1.7 and SET-2 cells were cultured for 12 h
oter.130  rev bras hematol hem
with CR-LAAO, in complete RPMI 1640 medium supplemented
with 10% fetal bovine serum, 2 mM glutamine, 100 U/mL peni-
cillin, 100 mg/mL  streptomycin, and 25 mM Hepes, under a
humidiﬁed 5% CO2 atmosphere at 37 ◦C.
Determination  of  the  enzymatic  activity  of  the  l-amino
acid  oxidase
Dr. Sandro Ghisla (University of Konstanz, Germany) kindly
provided the CR-LAAO, which was obtained according to the
method described by Macheroux et al.18 The enzymatic activ-
ity of CR-LAAO was determined in 0.1 M Tris–HCl buffer pH
7.2, at 25 ◦C. The qualitative test was performed to verify
whether the protein was active, which is a requisite for bio-
logical assays.
l-Amino  acid  oxidase  cytotoxicity  assay
The ability of living cells to reduce 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) to
insoluble violet formazan crystals was used as the parameter
to determine the cytotoxicity of CR-LAAO to HEL 92.1.7 and
SET-2 cells. Both cell lines (1 × 105 cells/well) were cultured in
96-well plates, in the presence of CR-LAAO (0.03–3.0 g/mL),
25 M etoposide (VP-16; positive control), or buffer (negative
control), for 12 h under a humidiﬁed 5% CO2 atmosphere at
37 ◦C. To assess the contribution of H2O2 to the overall effect
of CR-LAAO, both cell lines were treated with CR-LAAO in
combination with 150 U/mL catalase.
The plates were centrifuged at 240 × g for 10 min  at 4 ◦C
and 200 L of MTT  (5 mg/mL) were added to each well. After
4 h of incubation at 37 ◦C under 5% CO2, the formazan crys-
tals were dissolved by adding 100 L of a lysing solution (10%
sodium dodecyl sulfate plus 0.01 M HCl) to the wells. The ﬁnal
absorbance was recorded at 540 nm.  Controls in the absence of
CR-LAAO had 100% of cell viability. The percentage of cell via-
bility was calculated and used to determine the 50% inhibitory
concentration (IC50) values.
Measurement  of  apoptosis
HEL 92.1.7 and SET-2 cells (2 × 105 cells/well) were cultured in
24-well plates in the presence of CR-LAAO (0.05–2.5 g/mL),
for 12 h under a humidiﬁed 5% CO2 atmosphere at 37 ◦C. The
cells were washed with phosphate buffered saline at pH 7.4,
centrifuged, and suspended in 400 L of hypotonic ﬂuores-
cent solution (50 g/mL propidium iodide; Sigma–Aldrich, St.
Louis, MO, USA). After 45 min  of incubation at 4 ◦C in the dark,
the samples were analyzed in a FACSCanto ﬂow cytometer
(Becton-Dickinson, San Jose, CA, USA). Ten thousand events
were collected and analyzed by the Diva software and the
results are expressed as percentage of cells with hypodiploid
nuclei, which represent apoptotic cells.
Western  blotting  analysis  of  caspases  -3,  -8,  and  -9  and
cleaved  Poly(ADP-ribose)  polymeraseThe HEL 92.1.7 and SET-2 cells (1 × 106) treated with CR-
LAAO (0.03–0.15 g/mL and 1.5–3.0 g/mL, respectively) were
suspended in 200 L of the Western blotting sample buffer 2 0 1 6;3  8(2):128–134
supplemented with 5% mercaptoethanol, 4% sodium dodecyl
sulfate (SDS), 20% glycerol, and 100 mM Tris–HCl at pH 6.0.
The samples were analyzed by electrophoresis and transferred
onto polyvinylidene ﬂuoride (PVDF) membranes.
The membrane was sequentially labeled overnight
with anti-caspase-3 polyclonal rabbit antibody (code
9662, Cell Signaling Technology), anti-tubulin (code T3320,
Sigma–Aldrich), anti-caspase-9 polyclonal rabbit antibody
(code 9502, Cell Signaling Technology), anti-caspase-8 mouse
monoclonal antibody (code 9746, Cell Signaling Technology),
and anti-cleaved Poly(ADP-ribose) polymerase (PARP – code
9541, Cell Signaling Technology). The antibodies had been
diluted in a blocking solution containing 5% skim milk
and 0.01% sodium azide, according to the manufacturers’
instructions.
After labeling with each primary antibody, the membrane
was incubated with the peroxidase-labeled anti-mouse or
anti-rabbit secondary antibody for 1 h at room temperature.
The labeled proteins were detected by chemiluminescence
(Amersham ECL Plus, GE Healthcare Life Science, Pittsburgh,
BREAK). Then, the membrane was washed with the stripping
buffer before being relabeled with the next primary antibody.
Statistical  analysis
The percentages of cell viability and apoptosis of CR-LAAO-
treated HEL 92.1.7 and SET-2 cells were statistically compared
with their respective untreated controls, using one-way anal-
ysis of variance (ANOVA) and Dunnett’s post-test. To analyze
the effect of H2O2 on cell viability, the cell groups treated or
not with catalase were statistically compared using Student’s
t-test. Data were analyzed using the GraphPad Prism software
(v.5.0; Graph Pad Software, La Jolla, CA, USA). A p-value <0.05
was considered signiﬁcant.
Results
C.  rhodostoma  l-amino  acid  oxidase  decreases  the
viability  of  HEL  92.1.7  and  SET-2  cells  by  releasing  H2O2
Compared with the control, CR-LAAO diminished the viabil-
ity of HEL 92.1.7 and SET-2 cells in a concentration-dependent
manner, yielding the IC50 values of 0.15 and 1.5 g/mL, respec-
tively (Figure 1). The standard compound VP-16 decreased the
viability of both cell lines by nearly 96.7%.
To assess whether H2O2 mediates the cytotoxic effect of
CR-LAAO, the cells were treated with the toxin in combina-
tion with catalase. Catalase markedly changed the cytotoxic
proﬁle of CR-LAAO by increasing the viability of both cell lines
to 80–100% (Figure 2). Together, these results demonstrate that
(i) CR-LAAO is more  cytotoxic to HEL 92.1.7 cells than to SET-2
cells, and (ii) the H2O2 released during the enzymatic reaction
catalyzed by this oxidase mediates its cytotoxic action.
C.  rhodostoma  l-amino  acid  oxidase  induces  apoptosis  in
HEL 92.1.7  and  SET-2  cells  by  activating  caspases
To examine the apoptosis-inducing effect of CR-LAAO, the
formation of cells with hypodiploid nuclei was investigated
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Figure 1 – Cytotoxicity of l-amino acid oxidase from Calloselasma rhodostoma snake venom (CR-LAAO) to (A) HEL 92.1.7 and
(B) SET-2 JAK2V617F positive cells. C: negative control (culture medium). VP-16: 25 M etoposide (positive control).
Results are expressed as means ± standard deviation/standard error of the mean of triplicate assays. *p-value <0.05 vs. C
(one-way ANOVA).
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Figure 2 – l-Amino acid oxidase from Calloselasma rhodostoma snake venom (CR-LAAO) cytotoxicity, alone or in
combination with catalase to (A) HEL 92.1.7 and (B) SET-2 JAK2V617F-positive cells.
C: negative control (culture medium), ns: non-signiﬁcant. Results are expressed as means ± standard deviation/standard
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Figure 4 – Caspase activation in HEL 92.1.7 and SET-2 cells treated with the l-amino acid oxidase from Calloselasma
rhodostoma snake venom (CR-LAAO), detected by western-blotting. (A) Activation of caspases -3, -8 and cleaved PARP in HEL
ells. 92.1.7 cells. (B) Activation of pro-caspases 3 and 8 in SET-2 c
Discussion
Patients with Ph− MPN  such as PV, ET, and PMF  can display
extramedullary hematopoiesis, hyperplasia of megakary-
ocytes in the bone marrow, and varying degrees of dysplasia.
Progression of these MPN  types is marked by the appearance of
medullary ﬁbrosis (in patients with PV and ET) or transforma-
tion into either myelodysplastic syndrome or acute leukemia:
10% of the cases progress to acute myeloid leukemia.19
Description of the JAK2V617F mutation in 2005 prompted
the molecular study of the physiopathological mechanisms of
Ph− MPN.4 Expression of JAK2V617F induces the proliferation
of cell lines independently of their stimulation by cytokines
and growth factors. In murine experimental models, the retro-
viral expression of JAK2V617F in hematopoietic cells elicits the
development of a hematopoietic disease whose clinical signs
and symptoms resembles those of PV.4 The presence of the
JAK2V617F mutation correlates with the most severe clinical
and laboratory parameters in patients with PV, ET, and PMF,
which is characterized by increased hematocrit, hemoglobin
levels, leukocyte count, and neutrophil count; diminished
erythropoietin levels; hepatomegaly; splenomegaly; and ele-
vated incidence of thromboembolic events, when compared
with JAK2V617F-negative patients.20 Although the pathogen-
esis of MPN  are well known, scientists have still not discovered
an effective drug to treat and cure most of the patients with
PV, ET, and PMF.
Several researchers have described the resistance of
mononuclear cells to apoptosis and deregulation of the
expression of apoptosis-regulating genes in patients with PV,
ET, and PMF.9,21
Ruxolitinib, a JAK2 inhibitor, activates caspases -3, -8, and
-9 in speciﬁc cell lines,22 while diosgenin cleaves caspases -3,
-8, and -9 in HEL 92.1.7 cells.23 These reports underscore the
relevance of apoptosis activation for the antitumor effect of
new drugs against JAK2-mutated cells.
In the present study, the pro-apoptotic and cytotoxic poten-
tial of CR-LAAO was examined in HEL 92.1.7 and SET-2 cells
with the JAK2V617F mutation from patients with PV and ET
who  progressed to acute leukemia.Recent studies have demonstrated that H2O2 accounts
for the biological effects of CR-LAAO, including apoptosis
induction, which is an interesting therapeutic strategy to
treat neoplasms.24 The increased production of H2O2 andC: negative control (culture medium).
other reactive oxygen species elicits apoptosis by damaging
the mitochondrial membrane and promoting the release of
cytochrome c into the cytosol.25 In the present study, a 12-
h treatment with CR-LAAO signiﬁcantly reduced the viability
of HEL 92.1.7 and SET-2 cells; it indicates that CR-LAAO is
cytotoxic to JAK2V617F-positive cells from patients with PV,
ET, and PMF. Catalase mitigated the cytotoxicity of CR-LAAO,
demonstrating that H2O2 plays a central role in the cell death
process in JAK2-mutated cell lines. The fact that the HEL.92.1.7
cells were more  sensitive to the cytotoxic action of CR-LAAO
than the SET-2 cells is extremely relevant because the former
is homozygous for the JAK2V617F mutation, which makes it
more leukemogenic than the SET-2 cell line. These data also
stress that analysis of the overall effect of CR-LAAO in dif-
ferent cellular contexts can help to predict the effect of this
toxin in other mutated cell lines and in cells obtained from
JAK2V617F-positive patients with PV, ET, and PMF.
The mononuclear cells of healthy individuals are more
resistant to the action of CR-LAAO than the HEL.92.1.7 and
SET-2 cells, which suggests that CR-LAAO selectively induces
cytotoxicity in tumor cell lines.26 Although the antitumor
potential of snake venom LAAO (SV-LAAO) has already been
reported,15 this is the ﬁrst report on the action of CR-LAAO in
cell lines obtained from patients with Ph− MPN.
CR-LAAO also elicited apoptosis in HEL.92.1.7 and SET-2
cells by activating caspases -3, -8 and cleaved PARP. Cleavage
of pro-caspase-8 can either activate caspase-3 or elicit apo-
ptosis via the mitochondrial pathway or via BID cleavage. The
activation of pro-caspases -3 and -8 suggests activation of the
extrinsic pathway and BID cleavage. The extrinsic apoptosis
pathway is triggered by binding death receptors to their lig-
ands FAS (FAS/CD95), TNF-R1 and -R2, TRAIL R1 (DR4) and R2
(DR5), a family of transmembrane proteins bearing a cysteine-
rich extracellular domain and an intracellular DD. The signal
transduction via DD activates the working caspases -3, -6, and
-7 and elicits the subsequent formation of apoptotic bodies
(cell death).12
SV-LAAOs isolated from other species such as Ophiophagus
Hannah, Bothrops atrox, and Bungarus fasciatus are cyto-
toxic against gastric cancer, lung adenocarcinoma, murine
melanoma, promyelocytic leukemia, and breast cancer cell
lines; the toxins elicited the intrinsic and extrinsic apoptosis
pathways.27 It has been reported previously that LAAO iso-
lated from Bothrops pirajai snake venom elicits apoptosis and
potentiates the effect of imatinib mesylate – an inhibitor of
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cr-Abl tyrosine-kinase activity used to treat patients with
ML  – in Bcr-Abl-positive CML  cell lines.28 In line with these
ata, several studies reported that SV-LAAOs exert their cyto-
oxic action by releasing H2O2, which causes oxidative stress
nd consequent cell death in tumor cell lines.26,29 However,
atalase only partially inhibited the cytotoxicity of LAAO from
othrops leucurus.30 Therefore, not only the release of H2O2 but
lso other mechanisms may mediate the cytotoxic action of
V-LAAO.
In agreement with the aforementioned literature, the
esults of the present study show that SV-LAAOs act in H2O2-
ependent and -independent manners, depending on the
ellular context. Although the mechanism of action of CR-
AAO is poorly understood, the results of the current study
ndicate that this toxin is a potential antineoplastic agent
gainst JAK2V617F-positive cell lines, as demonstrated by its
bility to induce cytotoxicity and apoptosis of HEL 92.1.7 and
ET-2 cells. These ﬁndings may help to develop novel drugs
o treat Ph− MPN  as well as to improve current knowledge on
he snake envenomation mechanism. In addition, LAAOs can
e useful tools to investigate the biochemical pathways of the
poptosis process in tumor cells.
It is also important to point out that the present investiga-
ion showed results of a CR-LAAO cytotoxicity potential just
gainst JAK2V617F-positive cell lines. Thus, in order to conﬁrm
he CR-LAAO therapeutic potential against Ph− MPN, future
tudies using MPN  mice models and in primary samples from
yeloproliferative patients must be conducted to evaluate the
oxicity of the drug and the effect of the compound on primary
ells.
onclusions
he results of this study suggest that CR-LAAO has an anti-
eoplastic potential against HEL 92.1.7 and SET 2-JAK2 positive
ell lines demonstrated by the activation of extrinsic apop-
otic pathway, which may contribute to the description of new
rugs for the treatment the MPN.
onﬂicts  of  interest
he authors declare no conﬂicts of interest.
cknowledgements
he authors thank to São Paulo Research Foundation (FAPESP,
rants #2011/23236-4 and 2014/19127-3) and Research Sup-
ort Center on Animal Toxins of USP (NAP-TOXAN-USP, grant
12.1.17615.1.5).
 e  f  e  r  e  n  c  e  s
1. Campo E, Swerdlow SH, Harres NL, Pileri SA, Stein H, Jaffe ES.
The 2008 WHO  classiﬁcation of lymphoid neoplasms and
beyond: evolving concepts and practical applications. Blood.
2011;117(19):5019–32.
2. Spivak JL. Narrative review: thrombocytosis, polycythemia
vera, and JAK2 mutations – the phenotypic mimicry of 1 6;3  8(2):128–134 133
chronic myeloproliferation. Ann Int Med. 2010;152(5):
300–6.
3. Milosevic JD, Kralovics R. Genetic and epigenetic alterations
of myeloproliferative disorders. Int J Hematol. 2013;97(2):
183–97.
4. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout
C,  et al. A unique clonal JAK2 mutation leading to constitutive
signalling causes polycythaemia vera. Nature.
2005;434(7037):1144–8.
5. Vainchenker W,  Delhommeau F, Constantinescu SN, Bernard
OA. New mutations and pathogenesis of myeloproliferative
neoplasms. Blood. 2011;118(7):1723–35.
6. Jekarl DW, Han SB, Kim M, Lim J, Oh EJ, Kim Y, et al. JAK2
V617F mutation in myelodysplastic syndrome,
myelodysplastic syndrome/myeloproliferative neoplasm,
unclassiﬁable, refractory anemia with ring sideroblasts with
thrombocytosis and acute myeloid leukemia. Korean J
Hematol. 2010;45(1):46–50.
7. Tefferi A, Pardanani A. Genetics CALR mutations and a new
diagnostic algorithm for MPN. Nat Rev Clin Oncol.
2014;11(3):125–6.
8. Tognon R, Gasparotto EP, Leroy JM, Oliveira GL, Neves RP,
Carrara RC, et al. Differential expression of apoptosis-related
genes from death receptor pathway in chronic
myeloproliferative diseases. J Clin Pathol. 2011;64(1):
75–82.
9. Gasparotto EP, Tognon R, Ferrerira AF, Oliveira GL, Palma PV,
Zanichelli MA, et al. Deregulated expression of A1,  BCL-2,
BCL-XL and MCL-1 antiapoptotic proteins and BID, BAD and
BAX proapoptotic genes in Polycythemia vera patients. Braz J
Pharm Sci. 2011;47(4):873–86.
0. Dejean LM, Ryu SY, Martinez-Caballero S, Teijido O, Peixoto
PM, Kinnally KW. MAC and BCL-2 family proteins conspire in
a  deadly plot. Biochim Biophys Acta. 2010;1797(6–7):1231–8.
1. Hail-Junior N, Kim HJ, Lotan R. Mechanisms of
fenretinide-induced apoptosis. Apoptosis.
2006;11(10):1677–94.
2. Jin Z, El-Deiry WS. Overview of cell death signaling pathways.
Cancer Biol Ther. 2005;4(2):139–63.
3. Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives
on the treatment of patients with chronic myeloid leukemia:
an  individualized approach to treatment. Cancer J.
2007;13(6):357–65.
4. Choi CW, Bang SM, Jang S, Jung CW, Kim HJ, Kim HY, et al.
Guidelines for the management of myeloproliferative
neoplasms. Korean J Intern Med. 2015;30(6):771–88.
5. Costa TR, Menaldo DL, Silva CP, Sorrechia R, Albuquerque S,
Pietro RC, et al. Evaluating the microbicidal, antiparasitic and
antitumor effects of CR-LAAO from Calloselasma rhodostoma
venom. Int J Biol Macro. 2015;80:489–97.
6. Guo C1, Liu S, Yao Y, Zhang Q, Sun MZ. Past decade study of
snake venom l-amino acid oxidase. Toxicon.
2012;60(3):302–11.
7. Rodrigues RS, Silva JF, Franc¸a B, Fonseca FP, Otaviano AR, Silva
FH,  et al. Structural and functional properties of Bp-LAAO, a
new l-amino acid oxidase isolated from Bothrops pauloensis
snake venom. Biochimie. 2009;91(4):490–501.
8. Macheroux P, Seth O, Bollschweiler C, Schwarz M, Kurfürst M,
Au  LC, et al. l-Amino-acid oxidase from the Malayan pit viper
Calloselasma rhodostoma – comparative sequence analysis and
characterization of active and inactive forms of the enzyme.
Eur J Biochem. 2001;268(6):1679–86.
9. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y,
et  al. Treatment of progression of Philadelphia-negative
myeloproliferative neoplasms to myelodysplastic syndrome
or  acute myeloid leukemia by azacitidine: a report on 54 cases
on  the behalf of the Groupe Francophone des
Myelodysplasies (GFM). Blood. 2010;116(19):3735–42.
oter.
2
2
2
2
2
2
2
2
2
2134  rev bras hematol hem
0. Speletas M, Katodritou E, Daiou C, Mandala E, Papadakis E,
Kioumi A, et al. Correlations of JAK2-V617F mutation with
clinical and laboratory ﬁndings in patients with
myeloproliferative disorders. Leuk Res. 2007;31(8):
1053–62.
1. Tognon R, Gasparotto EP, Neves RP, Nunes NS, Ferreira AF,
Palma PV, et al. Deregulation of apoptosis-related genes is
associated with PRV1 overexpression and JAK2 V617F allele
burden in Essential Thrombocythemia and Myeloﬁbrosis. J
Hematol Oncol. 2012;5:2.
2. Szyman´ska J, Smolewski P, Majchrzak A, Cebula-Obrzut B,
Chojnowski K, Trelin´ski J. Pro-apoptotic activity of ruxolitinib
alone and in combination with hydroxyurea, busulphan, and
PI3K/mTOR inhibitors in JAK2-positive human cell lines. Adv
Clin Exp Med. 2015;24(2):195–202.
3. Cailleteau C, Liagre B, Beneytout JL. A proteomic approach to
the identiﬁcation of molecular targets in subsequent
apoptosis of HEL cells after diosgenin-induced
megakaryocytic differentiation. J Cell Biochem.
2009;107(4):785–96.4. Costa TR, Burin SM, Menaldo DL, Castro FA, Sampaio SV.
Snake venom l-amino acid oxidases: an overview on their
antitumor effects. J Venom Anim Toxins Incl Trop Dis.
2014;20:23.
3 2 0 1 6;3  8(2):128–134
5. Rakshit S, Mandal L, Pal BC. Involvement of ROS in
chlorogenic acid-induced apoptosis of Bcr-Abl+ CML cells.
Biochem Pharmacol. 2010;80(11):1662–70.
6. Ande SR, Kommoju PR, Draxl S, Murkovic M, Ghisla S,
Fröhlich KU, et al. Induction of apoptosis in yeast by l-amino
acid oxidase from the Malayan pit viper Calloselasma
rhodostoma.  Yeast. 2008;25(5):349–57.
7. Fung SY, Lee ML, Tan NH. Molecular mechanism of cell death
induced by king cobra (Ophiophagus hannah) venom l-amino
acid oxidase. Toxicon. 2015;96:38–45.
8. Burin SM, Ayres LR, Neves RP, Ambrosio L, Morais FR,
Dias-Barufﬁ M, et al. l-Amino acid oxidase isolated from
Bothrops pirajai induces apoptosis in BCR-ABL-positive cells
and potentiates imatinib mesylate effect. Basic Clin
Pharmacol Toxicol. 2013;113(2):103–12.
9. Bregge-Silva C, Nonato MC, de Albuquerque S, Ho PL, Azevedo
ILMJ, Diniz MRV, et al. Isolation and biochemical, functional
and structural characterization of a novel l-amino acid
oxidase from Lachesis muta snake venom. Toxicon.
2012;60(7):1263–76.0. Naumann GB, Silva LF, Silva L, Faria G, Richardson M,
Evangelista K, et al. Cytotoxicity and inhibition of platelet
aggregation caused by an l-amino acid oxidase from Bothrops
leucurus venom. Biochim Biophys Acta. 2011;1810(7):683–94.
